

## ClinicalTrials.gov Search Results 07/25/2022

	Title	Status	Study Results	Conditions	Interventions	Locations
1	<a href="#">Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease</a>	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Sickle Cell Disease</li> </ul>	<ul style="list-style-type: none"> <li>•Drug: CRISPR_SCD001</li> </ul>	<ul style="list-style-type: none"> <li>•University of California, Los Angeles, Los Angeles, California, United States</li> <li>•UCSF Benioff Children's Hospital, Oakland, California, United States</li> </ul>
2	<a href="#">Detection of Enterovirus Genotypes by CRISPR Technology</a>	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Enterovirus Infections</li> </ul>	<ul style="list-style-type: none"> <li>•Other: Non-invasive detection method: CRISPR technology</li> </ul>	
3	<a href="#">A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Gastrointestinal Epithelial Cancer</li> <li>•Gastrointestinal Neoplasms</li> <li>•Cancer of Gastrointestinal Tract</li> <li>•Cancer, Gastrointestinal</li> <li>•Gastrointestinal Cancer</li> <li>•Colo-rectal Cancer</li> <li>•Pancreatic Cancer</li> <li>•Gall Bladder Cancer</li> <li>•Colon Cancer</li> <li>•Esophageal Cancer</li> <li>•Stomach Cancer</li> </ul>	<ul style="list-style-type: none"> <li>•Drug: Cyclophosphamide</li> <li>•Drug: Fludarabine</li> <li>•Biological: Tumor-Infiltrating Lymphocytes (TIL)</li> <li>•Drug: Aldesleukin</li> </ul>	<ul style="list-style-type: none"> <li>•Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States</li> </ul>
4	<a href="#">Pathogenic Bordetella Rapid Detection</a>	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Pertussis</li> </ul>	<ul style="list-style-type: none"> <li>•Diagnostic Test: Detection pathogenic pertussis by cross primer constant temperature amplification (CPA) and drug resistant genes of erythromycin by CRISPR technology</li> </ul>	<ul style="list-style-type: none"> <li>•Children's Hospital of Fudan University, Shanghai, Shanghai, China</li> </ul>
5	<a href="#">Examining the Knowledge, Attitudes, and Beliefs of Sickle Cell Disease Patients, Parents of Patients With Sickle Cell Disease, and Providers Towards the Integration of CRISPR in Clinical Care</a>	Completed	No Results Available	<ul style="list-style-type: none"> <li>•Sickle Cell Disease</li> </ul>		<ul style="list-style-type: none"> <li>•National Human Genome Research Institute (NHGRI), Bethesda, Maryland, United States</li> </ul>
6	<a href="#">Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis</a>	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Viral Keratitis</li> <li>•Blindness Eye</li> <li>•Herpes Simplex Virus Infection</li> <li>•Cornea</li> </ul>	<ul style="list-style-type: none"> <li>•Drug: BD111 Adult single group Dose</li> </ul>	<ul style="list-style-type: none"> <li>•Eye &amp; Ent Hospital of Fudan University, Shanghai, Shanghai, China</li> </ul>
7	<a href="#">CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients</a>	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> <li>•COVID-19 Respiratory Infection</li> </ul>	<ul style="list-style-type: none"> <li>•Drug: PD-1 and ACE2 Knockout T Cells</li> </ul>	
8	<a href="#">Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Solid Tumor, Adult</li> </ul>	<ul style="list-style-type: none"> <li>•Biological: anti-mesothelin CAR-T cells</li> </ul>	<ul style="list-style-type: none"> <li>•Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital, Beijing, China</li> </ul>
9	<a href="#">CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Leukemia Lymphocytic Acute (ALL) in Relapse</li> <li>•Leukemia Lymphocytic Acute (All) Refractory</li> <li>•Lymphoma, B-Cell</li> <li>•CD19 Positive</li> </ul>	<ul style="list-style-type: none"> <li>•Genetic: XYF19 CAR-T cell</li> <li>•Drug: Cyclophosphamide</li> <li>•Drug: Fludarabine</li> </ul>	<ul style="list-style-type: none"> <li>•Xijing Hospital, Xi'an, Shannxi, China</li> </ul>

	Title	Status	Study Results	Conditions	Interventions	Locations
10	<a href="#">A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma</a>	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Multiple Myeloma</li> </ul>	<ul style="list-style-type: none"> <li>•Biological: CTX120</li> </ul>	<ul style="list-style-type: none"> <li>•University of Chicago, Chicago, Illinois, United States</li> <li>•Oregon Health and Science University, Portland, Oregon, United States</li> <li>•University of Pennsylvania, Philadelphia, Pennsylvania, United States</li> <li>•Sarah Cannon Research Institute, Nashville, Tennessee, United States</li> <li>•Royal Prince Alfred Hospital, Sydney, New South Wales, Australia</li> <li>•Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia</li> <li>•University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada</li> <li>•Institut Catala d'Oncologia Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain</li> <li>•Universidad de Navarra, Pamplona, Navarra, Spain</li> <li>•Hospital Universitario de Salamanca, Salamanca, Spain</li> </ul>
11	<a href="#">A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent #-Thalassemia</a>	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Beta-Thalassemia</li> <li>•Thalassemia</li> <li>•Genetic Diseases, Inborn</li> <li>•Hematologic Diseases</li> <li>•Hemoglobinopathies</li> </ul>	<ul style="list-style-type: none"> <li>•Biological: CTX001</li> </ul>	<ul style="list-style-type: none"> <li>•Stanford University, Stanford, California, United States</li> <li>•Ann &amp; Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States</li> <li>•Columbia University, Manhattan, New York, United States</li> <li>•The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers, Nashville, Tennessee, United States</li> <li>•Hospital for Sick Children, Toronto, Canada</li> <li>•BC Children's Hospital, Vancouver, Canada</li> <li>•University Hospital Duesseldorf, Düsseldorf, Germany</li> <li>•University Hospital Regensburg, Regensburg, Germany</li> <li>•University Hospital Tübingen, Tuebingen, Germany</li> <li>•Bambino Gesù, Rome, Italy</li> <li>•Imperial College Healthcare, London, United Kingdom</li> <li>•University College London Hospitals NHS Foundation Trust, London, United Kingdom</li> </ul>
12	<a href="#">A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Renal Cell Carcinoma</li> </ul>	<ul style="list-style-type: none"> <li>•Biological: CTX130</li> </ul>	<ul style="list-style-type: none"> <li>•Research Site 2, Duarte, California, United States</li> <li>•Research Site 5, Hartford, Connecticut, United States</li> <li>•Research Site 4, Houston, Texas, United States</li> <li>•Research Site 3, Salt Lake City, Utah, United States</li> <li>•Research Site 1, Melbourne, Victoria, Australia</li> <li>•Research Site 6, Toronto, Ontario, Canada</li> <li>•Research Site 7, Amsterdam, North Holland, Netherlands</li> </ul>

	Title	Status	Study Results	Conditions	Interventions	Locations
13	<a href="#">A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•T Cell Lymphoma</li> </ul>	<ul style="list-style-type: none"> <li>•Biological: CTX130</li> </ul>	<ul style="list-style-type: none"> <li>•Research Site 2, Duarte, California, United States</li> <li>•Research Site 5, Stanford, California, United States</li> <li>•Research Site 10, New Haven, Connecticut, United States</li> <li>•Research Site 4, Miami, Florida, United States</li> <li>•Research Site 8, Bronx, New York, United States</li> <li>•Research Site 9, New York, New York, United States</li> <li>•Research Site 1, Houston, Texas, United States</li> <li>•Research Site 6, Salt Lake City, Utah, United States</li> <li>•Research Site 3, Sydney, New South Wales, Australia</li> <li>•Research Site 7, Toronto, Ontario, Canada</li> </ul>
14	<a href="#">A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•B-cell Malignancy</li> <li>•Non-Hodgkin Lymphoma</li> <li>•B-cell Lymphoma</li> <li>•Adult B Cell ALL</li> </ul>	<ul style="list-style-type: none"> <li>•Biological: CTX110</li> </ul>	<ul style="list-style-type: none"> <li>•Cedars Sinai, Los Angeles, California, United States</li> <li>•UCSF Medical Center, San Francisco, California, United States</li> <li>•Mayo Clinic, Jacksonville, Florida, United States</li> <li>•Emory University Winship Cancer Institute, Atlanta, Georgia, United States</li> <li>•University of Chicago, Chicago, Illinois, United States</li> <li>•University of Kansas, Westwood, Kansas, United States</li> <li>•Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States</li> <li>•Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States</li> <li>•University of Minnesota, Minneapolis, Minnesota, United States</li> <li>•Washington University, Saint Louis, Missouri, United States</li> <li>•and 18 more</li> </ul>
15	<a href="#">CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Lymphoma, Non-Hodgkin</li> <li>•Relapsed Non Hodgkin Lymphoma</li> <li>•Refractory B-Cell Non-Hodgkin Lymphoma</li> <li>•Non Hodgkin Lymphoma</li> <li>•Lymphoma</li> <li>•B Cell Lymphoma</li> <li>•B Cell Non-Hodgkin's Lymphoma</li> </ul>	<ul style="list-style-type: none"> <li>•Genetic: CB-010</li> <li>•Drug: Cyclophosphamide</li> <li>•Drug: Fludarabine</li> </ul>	<ul style="list-style-type: none"> <li>•HonorHealth, Scottsdale, Arizona, United States</li> <li>•University of California San Diego Moores Cancer Center, La Jolla, California, United States</li> <li>•Chao Family Comprehensive Cancer Center/University of California Irvine, Orange, California, United States</li> <li>•Oncology Hematology Care, Cincinnati, Ohio, United States</li> <li>•Ohio State University James Cancer Hospital, Columbus, Ohio, United States</li> <li>•Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States</li> <li>•MD Anderson Cancer Center, Houston, Texas, United States</li> <li>•Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States</li> </ul>

	Title	Status	Study Results	Conditions	Interventions	Locations
16	<a href="#">A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease</a>	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Sickle Cell Disease</li> <li>•Hematological Diseases</li> <li>•Hemoglobinopathies</li> </ul>	•Biological: CTX001	<ul style="list-style-type: none"> <li>•Lucille Packard Children's Hospital of Stanford University, Palo Alto, California, United States</li> <li>•Ann &amp; Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States</li> <li>•University of Illinois at Chicago Hospitals and Health Systems, Chicago, Illinois, United States</li> <li>•Columbia University Medical Center (21+ years), New York, New York, United States</li> <li>•Columbia University Medical Center (#21 years), New York, New York, United States</li> <li>•Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States</li> <li>•St. Jude Children's Research Hospital, Memphis, Tennessee, United States</li> <li>•The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers, Nashville, Tennessee, United States</li> <li>•Methodist Children's Hospital/Texas Transplant Institute, San Antonio, Texas, United States</li> <li>•Hopital Universitaire des Enfants Reine Fabiola (HUDERF), Brussels, Belgium</li> <li>•and 7 more</li> </ul>
17	<a href="#">Species-specific Bacterial Detector for Fast Pathogen Diagnosis of Severe Pneumonia</a>	Not yet recruiting	No Results Available	•Severe Pneumonia	•Diagnostic Test: SSBD(PCR-CRISPR/ Cas12a)	<ul style="list-style-type: none"> <li>•The First People's Hospital of Changzhou, Changzhou, Jiangsu, China</li> <li>•Jiangsu Province hospital, Nanjing, Jiangsu, China</li> <li>•The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China</li> <li>•The Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China</li> <li>•Suzhou Manicipal Hospital, Suzhou, Jiangsu, China</li> </ul>
18	<a href="#">Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders</a>	Completed	No Results Available	•Kabuki Syndrome 1	•Genetic: Intervention on primary cultured cells	•Arnaud de villeneuve Hospital, Montpellier, Herault, France
19	<a href="#">A Safety and Efficacy Study Evaluating ET-01 in Subjects With Transfusion Dependent #-Thalassaemia</a>	Active, not recruiting	No Results Available	•Transfusion Dependent Beta-Thalassaemia	•Biological: ET-01	<ul style="list-style-type: none"> <li>•Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China</li> <li>•Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China</li> <li>•Shenzhen Children's Hospital, Shenzhen, Guangdong, China</li> <li>•Institute of Hematology &amp; Blood Diseases Hospital, Tianjin, Tianjin, China</li> </ul>
20	<a href="#">TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)</a>	Recruiting	No Results Available	•B Acute Lymphoblastic Leukemia	•Drug: PBLTT52CAR19	•Great Ormond Street Hospital, London, United Kingdom
21	<a href="#">An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Diabetes Mellitus</li> <li>•Diabetes Mellitus, Type 1</li> <li>•Glucose Metabolism Disorders</li> <li>•Metabolic Disease</li> <li>•Endocrine System Diseases</li> <li>•Autoimmune Diseases</li> <li>•Immune System Diseases</li> </ul>	•Combination Product: VCTX210A unit	<ul style="list-style-type: none"> <li>•University of Alberta, Edmonton, Alberta, Canada</li> <li>•University of British Columbia, Vancouver, British Columbia, Canada</li> <li>•LMC Manna, Toronto, Ontario, Canada</li> </ul>

	Title	Status	Study Results	Conditions	Interventions	Locations
22	<a href="#">Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent #-Thalassemia (TDT)</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Beta-Thalassemia</li> <li>•Thalassemia</li> <li>•Genetic Diseases, Inborn</li> <li>•Hematologic Diseases</li> <li>•Hemoglobinopathies</li> </ul>	•Biological: CTX001	•SCRI at the Children's Hospital at TriStar Centennial, Nashville, Tennessee, United States
23	<a href="#">Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Sickle Cell Disease</li> <li>•Hydroxyurea Failure</li> <li>•Hydroxyurea Intolerance</li> <li>•Hemoglobinopathies</li> <li>•Hematological Diseases</li> </ul>	•Biological: CTX001	•The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers, Nashville, Tennessee, United States
24	<a href="#">A Long-term Follow-up Study in Subjects Who Received CTX001</a>	Enrolling by invitation	No Results Available	<ul style="list-style-type: none"> <li>•Beta-Thalassemia</li> <li>•Thalassemia</li> <li>•Sickle Cell Disease</li> <li>•Hematologic Diseases</li> <li>•Hemoglobinopathies</li> <li>•Genetic Diseases, Inborn</li> <li>•Sickle Cell Anemia</li> </ul>	•Biological: CTX001	<ul style="list-style-type: none"> <li>•Columbia University Medical Center (21+ years), New York, New York, United States</li> <li>•Columbia University Medical Center, New York, New York, United States</li> <li>•St. Jude Children's Research Hospital, Memphis, Tennessee, United States</li> <li>•The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers, Nashville, Tennessee, United States</li> <li>•Methodist Healthcare System of San Antonio, Methodist Hospital, Methodist Children's Hospital, San Antonio, Texas, United States</li> <li>•The Hospital for Sick Children, Toronto, Canada</li> <li>•Toronto General Hospital, University Health Network, Toronto, Canada</li> <li>•St. Paul's Hospital, Vancouver, Canada</li> <li>•Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine, Regensburg, Germany</li> <li>•Universitätsklinikum Tübingen Klinik für Kinder- und Jugendmedizin, Tuebingen, Germany</li> <li>•Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesù - IRCCS, Rome, Italy</li> <li>•Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom</li> </ul>
25	<a href="#">Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•High Grade Ovarian Serous Adenocarcinoma</li> <li>•Stage III Ovarian Cancer AJCC v8</li> <li>•Stage IIIA Ovarian Cancer AJCC v8</li> <li>•Stage IIIA1 Ovarian Cancer AJCC v8</li> <li>•Stage IIIA2 Ovarian Cancer AJCC v8</li> <li>•Stage IIIB Ovarian Cancer AJCC v8</li> <li>•Stage IIIC Ovarian Cancer AJCC v8</li> <li>•Stage IV Ovarian Cancer AJCC v8</li> <li>•Stage IVA Ovarian Cancer AJCC v8</li> <li>•Stage IVB Ovarian Cancer AJCC v8</li> </ul>	<ul style="list-style-type: none"> <li>•Other: Biospecimen Collection</li> <li>•Other: Laboratory Biomarker Analysis</li> <li>•Device: Lavage</li> <li>•Other: Pap Smear</li> </ul>	•Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
26	<a href="#">PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer</a>	Completed	No Results Available	•Esophageal Cancer	•Other: PD-1 Knockout T Cells	•Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China

	Title	Status	Study Results	Conditions	Interventions	Locations
27	<a href="#">Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART</a>	Recruiting	No Results Available	•HIV-1-infection	•Biological: EBT-101	•Clinical Trial Site, San Francisco, California, United States •Washington University, Saint Louis, Missouri, United States •Cooper Health, Camden, New Jersey, United States
28	<a href="#">Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)</a>	Recruiting	No Results Available	•Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy •Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy •Wild-Type Transthyretin Cardiac Amyloidosis	•Biological: NTLA-2001	•Clinical Trial Site, Auckland, New Zealand •Clinical Trial Site, Umea, Sweden •Clinical Trial Site, London, United Kingdom
29	<a href="#">Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease</a>	Recruiting	No Results Available	•Sickle Cell Disease	•Genetic: GPH101 Drug Product	•University of Alabama at Birmingham, Birmingham, Alabama, United States •Lucile Packard Children's Hospital, Palo Alto, California, United States •Washington University, Saint Louis, Missouri, United States
30	<a href="#">Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia</a>	Recruiting	No Results Available	•Acute Myeloid Leukemia	•Genetic: Arm 1: NTLA-5001 •Genetic: Arm 2: NTLA-5001	•Research Site 2, Los Angeles, California, United States •Research Site 5, Tampa, Florida, United States •Research Site 1, Boston, Massachusetts, United States •Research Site 6, Portland, Oregon, United States •Research Site 3, Houston, Texas, United States •Research Site 4, Milwaukee, Wisconsin, United States •Research Site 10, Leeds, United Kingdom •Research Site 8, London, United Kingdom •Research Site 9, London, United Kingdom •Research Site 7, Manchester, United Kingdom
31	<a href="#">TGF#R-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors</a>	Recruiting	No Results Available	•Solid Tumor, Adult •EGFR Overexpression	•Biological: TGF#R-KO CAR-EGFR T Cells	•Chinese PLA General Hospital, Beijing, Beijing, China
32	<a href="#">Transplacental Transmission of RSV (TTRSV)</a>	Recruiting	No Results Available	•SARS CoV 2 Infection •Respiratory Syncytial Virus (RSV) •Bronchiolitis •Asthma		•Tulane University Lakeside Hospital, Metairie, Louisiana, United States •Ochsner Baptist Hospital, New Orleans, Louisiana, United States
33	<a href="#">PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer</a>	Completed	Has Results	•Metastatic Non-small Cell Lung Cancer	•Drug: Cyclophosphamide •Other: PD-1 Knockout T Cells	•West China Hospital, Sichuan University, Chengdu, Sichuan, China
34	<a href="#">Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies</a>	Not yet recruiting	No Results Available	•CD5+ Relapsed/Refractory Hematopoietic Malignancies •Chronic Lymphocytic Leukemia (CLL) •Mantle Cell Lymphoma (MCL) •Diffuse Large B-cell Lymphoma (DLBCL) •Follicular Lymphoma (FL) •Peripheral T-cell Lymphomas (PTCL)	•Biological: CT125A cells •Drug: Cyclophosphamide, fludarabine	
35	<a href="#">Study of Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7)</a>	Recruiting	No Results Available	•Relapsed/Refractory T-cell Acute Lymphoid Leukaemia	•Biological: Cryopreserved BE CAR7 T cells (BE752TBCCLCAR7PBL)	•Ilyas Ali, London, United Kingdom
36	<a href="#">Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101</a>	Enrolling by invitation	No Results Available	•HIV-1-infection	•Biological: EBT-101	•Clinical Trial Site, San Francisco, California, United States •Washington University, Saint Louis, Missouri, United States •Cooper Health, Camden, New Jersey, United States



	Title	Status	Study Results	Conditions	Interventions	Locations
37	<a href="#">A Long-term Follow-up Study of Patients Who Received VOR33</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>Leukemia, Myeloid, Acute</li> </ul>	<ul style="list-style-type: none"> <li>Genetic: VOR33</li> </ul>	<ul style="list-style-type: none"> <li>University of California San Diego Moores Cancer Center, La Jolla, California, United States</li> <li>Miami Cancer Institute, Miami, Florida, United States</li> <li>Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States</li> <li>John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States</li> <li>Memorial Sloan Kettering Cancer Center, New York, New York, United States</li> <li>University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States</li> <li>Fred Hutchinson Cancer Research Center, Seattle, Washington, United States</li> <li>Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada</li> </ul>
38	<a href="#">Novel SARS-CoV-2 Point-of-care Testing</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>SARS-CoV2 Infection</li> </ul>	<ul style="list-style-type: none"> <li>Other: no intervention</li> </ul>	<ul style="list-style-type: none"> <li>Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong, Hong Kong</li> </ul>
39	<a href="#">NTLA-2002 in Adults With Hereditary Angioedema (HAE)</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>Hereditary Angioedema</li> </ul>	<ul style="list-style-type: none"> <li>Biological: Biological NTLA-2002</li> <li>Other: Normal Saline IV Administration</li> </ul>	<ul style="list-style-type: none"> <li>Academic Medical Center - University of Amsterdam, Amsterdam, Netherlands</li> <li>Study Site, Auckland, New Zealand</li> <li>Cambridge University Hospitals NHS Foundation Trust Addenbrookes Hospital, Cambridge, United Kingdom</li> </ul>
40	<a href="#">A Clinical Evaluation of Proof Diagnostics Test System Including the Proof Diagnostics Reader and COVID-19 Test</a>	Completed	No Results Available	<ul style="list-style-type: none"> <li>COVID-19</li> <li>Asymptomatic COVID-19</li> </ul>	<ul style="list-style-type: none"> <li>Diagnostic Test: Proof Lab Test System</li> </ul>	<ul style="list-style-type: none"> <li>Asclepes Research Center, Spring Hill, Florida, United States</li> <li>PMG Research of Piedmont Healthcare, Statesville, North Carolina, United States</li> <li>Eastside Research Associates, Redmond, Washington, United States</li> </ul>
41	<a href="#">A Clinical Evaluation of Pine Trees Health Test System Including the Pine Trees Health Reader and COVID-19 Test for Point-of-Care</a>	Completed	No Results Available	<ul style="list-style-type: none"> <li>SARS (Severe Acute Respiratory Syndrome)</li> <li>Covid19</li> </ul>	<ul style="list-style-type: none"> <li>Diagnostic Test: The Pine Trees Health Test System</li> </ul>	<ul style="list-style-type: none"> <li>ASCLEPES Research Center, Spring Hill, Florida, United States</li> <li>PMG Research of Piedmont Healthcare, Statesville, North Carolina, United States</li> <li>Eastside Research Associates, Redmond, Washington, United States</li> </ul>
42	<a href="#">Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>Nasopharyngeal Carcinoma</li> </ul>	<ul style="list-style-type: none"> <li>Diagnostic Test: EBV antibodies test</li> <li>Diagnostic Test: EBV DNA test</li> </ul>	<ul style="list-style-type: none"> <li>Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China</li> </ul>
43	<a href="#">EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>Transfusion Dependent Beta Thalassemia</li> <li>Hemoglobinopathies</li> <li>Thalassemia Major</li> <li>Thalassemia Intermedia</li> </ul>	<ul style="list-style-type: none"> <li>Genetic: EDIT-301</li> </ul>	<ul style="list-style-type: none"> <li>Tristar Medical Group Children's Specialists/Sarah Cannon Center for Blood Cancers, Nashville, Tennessee, United States</li> </ul>
44	<a href="#">Single Ascending Dose Study in Participants With LCA10</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>Leber Congenital Amaurosis 10</li> <li>Inherited Retinal Dystrophies</li> <li>Eye Diseases, Hereditary</li> <li>Retinal Disease</li> <li>Retinal Degeneration</li> <li>Vision Disorders</li> <li>Eye Disorders Congenital</li> </ul>	<ul style="list-style-type: none"> <li>Drug: EDIT-101</li> </ul>	<ul style="list-style-type: none"> <li>Bascom Palmer Eye Institute, Miami, Florida, United States</li> <li>Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States</li> <li>W.K. Kellogg Eye Center - University of Michigan, Ann Arbor, Michigan, United States</li> <li>Casey Eye Institute - OSHU, Portland, Oregon, United States</li> <li>University of Pennsylvania, Philadelphia, Pennsylvania, United States</li> </ul>

	Title	Status	Study Results	Conditions	Interventions	Locations
45	<a href="#">Characterization of a Functional Test for Mediterranean Family Fever Screening - 2</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Familial Mediterranean Fever</li> <li>•MEFV Gene Mutation</li> </ul>	<ul style="list-style-type: none"> <li>•Biological: one additional blood sample during a planned blood test</li> </ul>	<ul style="list-style-type: none"> <li>•Hôpital Femme-Mère-Enfant, Bron, France</li> <li>•CH de Versailles - Hôpital André Mignot, Le Chesnay, France</li> <li>•Hôpital Edouard Herriot, Lyon, France</li> <li>•Hôpital de la Croix-Rousse, Lyon, France</li> <li>•CHU de Montpellier, Montpellier, France</li> <li>•Service de Pédiatrie - CHU de Nîmes - Hôpital Carémeau, Nîmes, France</li> <li>•Hôpital Tenon, Paris, France</li> <li>•Hôpital Lyon Sud, Pierre-Bénite, France</li> </ul>
46	<a href="#">Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.</a>	Recruiting	No Results Available	<ul style="list-style-type: none"> <li>•Rubinstein-Taybi Syndrome</li> </ul>	<ul style="list-style-type: none"> <li>•Procedure: skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 SRT patients included.</li> <li>•Other: Generation of Induced Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsy</li> <li>•Other: Histone acetylation profiles of cells of SRT patients with CREBBP mutations</li> <li>•Other: Functional involvement of identified epigenetic alterations</li> <li>•Biological: Culture of lymphoblastoid line from blood sample</li> </ul>	<ul style="list-style-type: none"> <li>•Centre Hospitalier Universitaire de Bordeaux, Talence, France</li> </ul>
47	<a href="#">A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne</a>	Completed	Has Results	<ul style="list-style-type: none"> <li>•Acne Vulgaris</li> </ul>	<ul style="list-style-type: none"> <li>•Biological: NB01</li> </ul>	<ul style="list-style-type: none"> <li>•Dermatology Research Associates, Los Angeles, California, United States</li> </ul>